毒素用于症的管理:审查协议概述的概述
Manuella Salm Coelho1, Júlia Meller Dias de Oliveira1, Helena Polmann2
1Department of Dentistry, University of Santa Catarina, Florianópolis, Brazil.
BMJ open
|October 10, 2024
概括
这项研究回顾了关于毒素A型 (BoNT-A) 用于布鲁克斯症管理的现有研究. 它旨在澄清BoNT-A的目的.
科学领域:
- 神经学 神经学
- 牙科 牙科是指牙科的专业.
- 药理学 药理学是指药理学的学科.
背景情况:
- Bruxism 涉及重复的肌活动,包括牙紧握或磨牙.
- 管理通常在不良影响显现后开始.
- 甲型玻尿素毒素 (BoNT-A) 是一种潜在的干预措施,但其对乳头的疗效仍有争议.
研究的目的:
- 系统地审查和综合证据,证明BoNT-A对治疗成年人乳症的有效性.
- 为了比较BoNT-A与安慰剂,没有治疗或替代干预措施的疗效.
主要方法:
- 有或没有元分析的系统性审查 (SRs) 的概述.
- 在多个数据库和灰色文献中进行全面的文献搜索.
- 使用AMSTAR-II和叙事合成进行数据分析的SRs的方法质量评估.
主要成果:
- 概述综合了BoNT-A对成年bruxism的现有SRs的发现.
- 结果将解决与对照条件相比BoNT-A的有争议的疗效.
- 数据将使用叙事合成和重叠量化来分析.
结论:
- 这一概述将提供对BoNT-A在布鲁克斯症治疗中的作用的综合理解.
- 结果将为临床实践和未来的研究方向提供信息.
- 传播将通过发表在具有影响力的期刊中进行.
相关概念视频
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
658
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
658
Skeletal Muscle Relaxants: Therapeutic Uses
470
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
470
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
397
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
397
Classification of Skeletal Muscle Relaxants
2.4K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.4K
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
3.2K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
3.2K
Depolarizing Blockers: Pharmocokinetics
313
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
313


